Review: Item Analysis of ADAS-Cog: Effect of Baseline Cognitive Impairment in a Clinical AD Trial

Abstract

We explored the association of Alzheimer’s disease (AD) Assessment Scale (ADAS-Cog) item scores with AD severity using cross-sectional and longitudinal data from the same study. Post hoc analyses were performed using placebo data from a 12-month trial of patients with mild-to-moderate AD (N = 281 randomized, N = 209 completed). Baseline distributions of ADAS-Cog item scores by Mini-Mental State Examination (MMSE) score and Clinical Dementia Rating (CDR) sum of boxes score (measures of dementia severity) were estimated using local and nonparametric regressions. Mixed-effect models were used to characterize ADAS-Cog item score changes over time by dementia severity (MMSE: mild = 21-26, moderate = 14-20; global CDR: mild = 0.5-1, moderate = 2). In the cross-sectional analysis of baseline ADAS-Cog item scores, orientation was the most sensitive item to differentiate patients across levels of cognitive impairment. Several items showed a ceiling effect, particularly in milder AD. In the longitudinal analysis of change scores over 12 months, orientation was the only item with noticeable decline (8%-10%) in mild AD. Most items showed modest declines (5%-20%) in moderate AD.

Keywords

Alzheimer’s disease assessment scale ADAS-Cog item analysis randomized controlled clinical trial placebo

References

Rosen WG , Mohs RC , Davis KL A new rating scale for Alzheimer’s disease. Am J Psychiatry . 1984;141(11):1356-1364.

Zec RF , Landreth ES , Vicari SK , et al. Alzheimer disease assessment scale: useful for both early detection and staging of dementia of the Alzheimer type. Alzheimer Dis Assoc Disord. 1992;6(2): 89-102.

Stern RG , Mohs RC , Davidson M. , et al. A longitudinal study of Alzheimer’s disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry . 1994;151(3):390-396.

Schmeidler J. , Mohs RC , Aryan M. Relationship of disease severity to decline on specific cognitive and functional measures in Alzheimer disease. Alzheimer Dis Assoc Disord. 1998 ;12(3):146-151.

Sevigny JJ , Ryan JM , van Dyck CH , et al. Growth hormone secretagogue MK-677: No clinical effect on AD progression in a randomized trial. Neurology. 2008;71(21):1702-1708.

Mckhann G. , Drachman D. , Folstein M. , et al. Clinical-Diagnosis of Alzheimers-Disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984; 34:939-944.

Morris JC The Clinical Dementia Rating (CDR): current version and scoring rules . Neurology. 1993;43(11):2412-2414.

Folstein MF , Folstein SE , McHugh PR " Mini-mental state’’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.

Rosen WG , Terry RD , Fuld PA , Katzman R. , Peck A. Pathological verification of ischemic score in differentiation of dementias . Ann Neurol. 1980;7(5):486-488.

10.

Cleveland WS , Devlin SJ Locally weighted regression: an approach to regression analysis by local fitting. J Am Stat Assoc. 1988;83(403):596-610.

11.

Zec RF , Landreth ES , Vicari SK , et al. Alzheimer Disease Assessment Scale: a subtest analysis. Alzheimer Dis Assoc Disord. 1992; 6(3):164-181.

12.

Amatniek J. , Zhu Y. , Crivera C. , et al. Item response models for Alzheimer’s Disease Assessment Scale (ADAS-COG): using placebo and baseline data from clinical trials with galantamine. Abstract presented at 11th Congress of the European Federation of Neurological Societies, August 25-28, 2007; Brussels, Belgium. Eur J Neurol . 2007;14(suppl 1):48. http://www.kenes.com/efns2007 Accessed November 20, 2008.

13.

Doraiswamy PM , Kaiser L. , Bieber F. , et al. The Alzheimer’s Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer’s disease . Alzheimer Dis Assoc Disord. 2001 ;15(4):174-183.

14.

Irizarry MC , Webb DJ , Bains C. , et al. Predictors of placebo group decline in the Alzheimer’s disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer’s disease . J Alzheimers Dis. 2008;14(3):301-311.